Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts.

The Karnataka High Court has stayed an advisory issued by the Food Safety and Standards Authority of India (FSSAI) banning the use of Ashwagandha leaves or extracts in supplements due to safety concerns flagged by the Union Ministry of Ayush.

Justice S R Krishna Kumar Tuesday said, “The impugned advisory dated 16.04.2026 issued by the respondents is hereby stayed only insofar as it relates to the petitioners in W.P.No.14990/2026 and W.P.No.15010/2026 are concerned, till the next date of hearing.”

The interim order was passed in response to petitions filed by Sami-Sabinsa Group Ltd and Kerry Inc, which approached the court seeking to quash the advisory.

Ashwagandha, as an adaptogen, is commonly marketed as a natural supplement to boost strength and sexual wellness, particularly among men, and is available in various forms. Ashwagandha leaves allegedly contain higher levels of reactive withanolides, particularly withaferin-A, that pose safety risks including liver toxicity, gastrointestinal distress, and potential neurotoxic effects.

Senior Advocate K G Raghavan, appearing for the petitioners, argued that the companies are engaged in the manufacture of their products through contract manufacturers of Ashwagandha.

Further it was said that the manufacturing of Ashwagandha from the roots and extracts of the plant including leaves is being done as per norms laid down under Food Safety and Standards (Health Supplements, Neutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, which are framed under Section 92 of the Food Safety and Standards Act, 2006.

Raghavan also pointed out that the prohibition of the usage of certain parts of a food supplement cannot be issued through a mere advisory, without amending the 2016 Regulations. Moreover, the companies have been manufacturing their products using the leaves of the Ashwagandha plant for more than 30 years.

Related Posts

SS Innovations International aces Race beating Global Giants in Surgical Robotics

In a First to India, Maker of Surgical Robot SSiMantra, brings ultimate Laurel New Delhi: Indian Medtech company SS Innovations’ SSiMantra, the best in class only ‘Made in India’ surgical…

India curbs supply of IVF consumables to unregistered clinics

The move comes amid growing concerns over the proliferation of fertility centres in India, one of the world’s fastest-growing IVF markets. New Delhi: India is moving to cut off supplies…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

SS Innovations International aces Race beating Global Giants in Surgical Robotics

SS Innovations International aces Race beating Global Giants in Surgical Robotics

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

India curbs supply of IVF consumables to unregistered clinics

India curbs supply of IVF consumables to unregistered clinics

Maha FDA seizes counterfeit skincare products; FIR registered

Maha FDA seizes counterfeit skincare products; FIR registered

RMSCL MD Inspects Rajasthan Sampark Portal; Directs Prompt Resolution of Medicine-Related Grievances

RMSCL MD Inspects Rajasthan Sampark Portal; Directs Prompt Resolution of Medicine-Related Grievances

4 arrested in blood plasma adulteration racket

4 arrested in blood plasma adulteration racket